3 cheap dividend shares to buy

Rupert Hargreaves takes a look at three dividend shares trading at attractive valuations that he would buy for his portfolio today.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

I am always looking for dividend shares to buy for my portfolio. I like to concentrate on cheap dividend shares because this builds a margin of safety into my analysis. It also provides scope for capital growth as well as income if market sentiment towards these companies improves. 

A portfolio of dividend shares

A great example is GlaxoSmithKline (LSE: GSK). The international pharmaceuticals group is currently trading at a forward price-to-earnings ratio of 13.8. That looks cheap compared to the global pharmaceuticals sector. It also offers a dividend yield of 4.4% at the time of writing.

These metrics alone look attractive. However, the company is also planning to spin off its consumer healthcare business in the near term. Management has said the firm will cut its dividend after the spin-off, which is disappointing, but I think the two organisations will be worth more separately than they are together. 

That is the main reason why I would buy the stock for my portfolio of dividend shares today. Unfortunately, there is no guarantee the spin-off will create value. Glaxo has also struggled to achieve earnings growth in recent years, weighing on the firm’s equity. So, there are plenty of challenges the group may have to overcome. 

Steady income 

Considering the uncertainties outlined above, I appreciate Glaxo might not be suitable for all investors. Another company I would buy for my portfolio of dividend shares is the insurance group Direct Line (LSE: DLG). 

The best income stocks have predictable profits. Companies that sell products or services on a subscription basis are fantastic examples. Direct Line has similar qualities. Consumers tend to renew their insurance policies every year, and car insurance is a legal requirement. 

These qualities suggest to me that the company’s profits are predictable. That is why I would buy the stock and its 7.9% dividend yield for my portfolio today. The shares are also selling at an inexpensive looking price-to-earnings (P/E) multiple of 11.5. 

One challenge the company may face as we advance is climate change. This could lead to a higher volume of extreme weather-related claims. If claims costs begin to increase rapidly, Direct Line may have no choice but to reduce its distributions to investors. 

Undervalued 

The final company I would buy for my portfolio of cheap dividend shares is real estate investment trust (REIT) NewRiver (LSE: NRR). 

The company, which owns a portfolio of properties in the retail and leisure sectors across the UK, is a recovery play. Commercial property values have plunged over the past 18 months, as landlords have struggled to collect rents. NewRiver’s share price performance since March last year reflects this uncertain environment. 

While uncertainty could persist for some time, it is clear that as the UK economy recovers, consumers are returning to the high street. This should have a positive impact on commercial property values.

Despite the improving outlook, shares in NewRiver are still selling at a 50% discount to the firm’s book value. I think this is too cheap. The stock also yields 9%. Considering this level of income and the company’s valuation, I would buy the stock for my portfolio of dividend shares. 

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Rupert Hargreaves owns shares of Direct Line Insurance. The Motley Fool UK has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »